ORANGE COUNTY, Calif. (April 29, 2024) – Beckman
Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel
of conjugated-antibody cocktails for the characterization of
hematolymphoid neoplasia by flow cytometry. The pre-mixed and
ready-to-use panels target the appropriate markers as recommended
by the 2006 Bethesda International Consensus and are compatible
with the WHO Classification of Tumors of Hæmatopoietic and
Lymphoid Tissues (2008 revised).
The panels allow for the identification and enumeration of a
comprehensive combination of markers and offer full regulatory
compliance.* They can be used as an aid in the investigation of
patients with abnormal hematology in order to provide data critical
in the diagnosis, staging and prognosis of hematolymphoid
neoplasia. Twenty-three markers are combined in seven tubes
-- two tubes in the B-cell lineage kit, two tubes in the T-cell
lineage kit, and three tubes in the myelomonocytic lineage kit --
each tube containing up to five relevant antibodies. Kits can be
run individually or jointly and the preparation procedure is
designed to offer standardization, consistency and simplicity.
The Solastra panels will streamline testing in the laboratory.
Joanne Luider, (BSC ART MLT, Calgary Laboratory Services, Alberta,
Canada) calculates the number of pipetting steps is reduced by up
to 55 percent versus home-brew with single-color reagents. "The
pre-mixed formulation minimizes preparation time, which for a busy
lab like ours, saves over half a day a week on cocktail
preparation,” said Luider. "In addition, being ready-to-use
reduces the probability of pipetting errors."
Patients will benefit from the highly sensitive and accurate
testing the kits provide. "The launch of our Solastra antibody
cocktails for hematolymphoid neoplasia analysis represents a
significant step forward in simplification and standardization in
this field,” said Brad Calvin, vice president of Beckman
Coulter's Flow Cytometry Business Center. "By following
international consensus, developing pre-mixed cocktails and
validating them in multi-site trials, we have reduced the burden
and improved the reliability for performing these tests."
In addition to CD45, which is included in all seven tubes, the
markers represented in the B-cell lineage kit are CD5, CD10, CD19,
CD20, CD38, Kappa and Lambda. Tubes in the T-cell lineage kit
offer CD2, CD3, CD4, CD5, CD7, CD8 and CD56. The
myelomonocytic lineage kit tubes contain CD7, CD11b, CD13, CD14,
CD15, CD16, CD33, CD34, CD56, CD117 and HLA-DR. Each antibody is
conjugated to one of five dyes: FITC, PE, ECD (PE-Texas Red**),
PC5.5 (PE-Cyanine 5.5) and PC7 (PE-Cyanine 7). Proprietary tandem
dye technology allows Beckman Coulter to produce conjugates that
are stable, bright and consistent from lot-to-lot.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California,
develops, manufactures and markets products that simplify,
automate and innovate complex biomedical tests. More than
200,000 Beckman Coulter systems operate in laboratories around the
world, supplying critical information for improving patient health
and reducing the cost of care. Recurring revenue, consisting of
consumable supplies (including reagent test kits), service and
operating-type lease payments, represent about 80 percent of the
company's 2009 revenue of $3.3 billion. For more information, visit
http://www.beckmancoulter.com/.
*Per the requirements of the European In Vitro Diagnostics
Directive (98/79/EC). Not available in the U.S., pending
submission and clearance by the U.S. FDA.
**Texas-Red is a trademark of Molecular Probes, Inc.
Beckman Coulter and the stylized logo are registered trademarks of
Beckman Coulter, Inc.
SOURCE